
Subcutaneous Isatuximab Meets Primary End Points in Phase 3 Study for MM
Key Takeaways
- The SC formulation of isatuximab showed noninferiority to the IV version in the phase 3 IRAKLIA study for multiple myeloma.
- The study used an on-body delivery system, enhancing patient convenience and reducing infection risk compared with IV administration.
If the subcutaneous delivery method gains approval, an advantage daratumumab holds over isatuximab would be removed.
A subcutaneous (SC) formulation of isatuximab (Sarclisa, Sanofi) was found to be just as effective as the intravenous version of the drug in treating multiple myeloma, which could pave the way for an approval that would remove a major advantage for a competitor.
In
“The consistent overall response rate and comparable efficacy and safety profile observed in the IRAKLIA study for subcutaneous [isatuximab] represent an exciting advancement, offering insight into a potential new administration option for patients,” principal investigator Sikander Ailawadhi, MD, professor of medicine, Division of Hematology/Oncology at Mayo Clinic Florida, said
SC administration has gained ground over IV administration of cancer therapies over the past decade, for reasons of patient convenience, lower cost, and reduced risk of infection. Another anti-CD38 monoclonal antibody, daratumumab (Darzalex, Johnson & Johnson), is already available in an SC formulation.
Isatuximab binds to a specific epitope on the CD38 receptor on myeloma cells, producing a distinct antitumor response. It works through multiple pathways, including direct apoptosis, crosslinking of CD38 and CD16, and by sensitizing T cells against CD38-positive cells. Daratumumab has some mechanisms of action that are similar to isatuximab but not direct apoptosis.
Both isatuximab and daratumumab
In the IRAKLIA study, investigators used an OBDS developed by Enable Injections, which
In the trial involving patients with relapsed or refractory multiple myeloma, isatuximab was administered at a fixed SC dose via the Enfuse OBDS in combination with pomalidomide and dexamethasone. Sanofi officials said the study met coprimary end points of noninferior objective response rate and observed observed concentration before dosing at a steady state, compared with IV isatuximab at a weight-based dose in combination with pomalidomide and dexamethasone.
Key secondary end points, which included very good partial response (VGPR), and incidence rate of infusion reactions were also achieved. Full results of the ongoing study will be presented at a future medical meeting. Additional studies evaluating SC formulations of isatuximab across different combinations and lines of therapy are ongoing. According to the statement, regulatory submissions in the United States and Europe are anticipated in the first half of this year.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.